DNA Vaccine for Ragweed Allergic Adults
Palabras clave
Abstracto
Descripción
Evaluation of efficacy and safety of allergen-CpG oligonucleotide immunostimulatory conjugate in treatment of ragweed-induced seasonal allergic rhinitis. Study incorporates clinical outcomes (symptom diaries, medication diaries, visual analog scores, quality of life questionnaires), safety measurements, immunologic assays (antibody measurements, T-cell assays, cytokine assays, nasal provocation).
fechas
| Verificado por última vez: | 11/30/2018 |
| Primero enviado: | 06/26/2006 |
| Inscripción estimada enviada: | 06/26/2006 |
| Publicado por primera vez: | 06/28/2006 |
| Última actualización enviada: | 12/11/2018 |
| Última actualización publicada: | 12/12/2018 |
| Fecha de inicio real del estudio: | 05/17/2001 |
| Fecha estimada de finalización primaria: | 08/20/2001 |
| Fecha estimada de finalización del estudio: | 08/20/2001 |
Condición o enfermedad
Intervención / tratamiento
Drug: AIC (Amb a 1 Immunostimulatory Conjugate)
Fase
Criterio de elegibilidad
| Edades elegibles para estudiar | 18 Years A 18 Years |
| Sexos elegibles para estudiar | All |
| Acepta voluntarios saludables | si |
| Criterios | Inclusion Criteria: - Adult men and women 18 to 60 years of age; - Who provide informed consent; - Have a history of fall, seasonal, allergic rhinitis consistent with ragweed allergy; - Exhibit a positive skin test to licensed , standardized, ragweed extract and a positive acute response to ragweed nasal challenge; - Are in general good health; and are available for the duration of the study. Exclusion Criteria: - Individuals with medical conditions or taking medications that might interfere with interpretation of the study results will be excluded. - Those with a history of severe symptoms of allergic rhinitis during the spring and summer grass pollen season will be excluded. |
Salir
Medidas de resultado primarias
1. Effect of treatment on nasal allergen challenge [undefined]
